Patents by Inventor DAW-TSUN SHIH

DAW-TSUN SHIH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF
    Publication number: 20230382988
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Application
    Filed: March 6, 2023
    Publication date: November 30, 2023
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • Compound targeting IL-23A and TNF-alpha and uses thereof
    Patent number: 11680096
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: June 20, 2023
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, MACROGENICS, INC.
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • Anti-colony stimulating factor 1 receptor (CSF1R) antibodies and methods of use thereof for treating cancer
    Patent number: 11396549
    Abstract: The present disclosure provides antibodies, including antibody fusions, which specifically bind to human CSF1 receptor protein (huCSF1R) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by huCSF1R, such as regulation of TAMs in the tumor microenvironment. Additionally, the antibodies include fusions with the cytokine inhibitory factor, IL10, which can replenish and/or activate CD8+ T-cell cytotoxicity in the tumor microenvironment. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CSF1 binding to CSF1R.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: July 26, 2022
    Assignee: ELIXIRON IMMUNOTHERAPEUTICS (HONG KONG) LIMITED
    Inventors: Hung-Kai Chen, Daw-Tsun Shih, Jing-Yi Huang, Huey-Wen Hsiao, Chih-Lun Hsiao
  • ANTI-CSF1R ANTIBODIES, IL10 FUSION PROTEINS, AND USES THEREOF
    Publication number: 20210403583
    Abstract: The present disclosure provides antibodies, including antibody fusions, which specifically bind to human CSF1 receptor protein (huCSF1R) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by huCSF1R, such as regulation of TAMs in the tumor microenvironment. Additionally, the antibodies include fusions with the cytokine inhibitory factor, IL10, which can replenish and/or activate CD8+T-cell cytotoxicity in the tumor microenvironment. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CSF1 binding to CSF1R.
    Type: Application
    Filed: August 31, 2021
    Publication date: December 30, 2021
    Applicant: ELIXIRON IMMUNOTHERAPEUTICS (HONG KONG) LIMITED
    Inventors: Hung-Kai CHEN, Daw-Tsun SHIH, Jing-Yi HUANG, Huey-Wen HSIAO, Chih-Lun HSIAO
  • COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF
    Publication number: 20210054065
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Application
    Filed: August 26, 2020
    Publication date: February 25, 2021
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • Methods for treatment of HBV infection
    Patent number: 10813974
    Abstract: The present invention provides methods for treating hepatitis B virus (HBV) infection using antibodies which specifically bind to human IFN?.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: October 27, 2020
    Assignee: ELIXIRON IMMUNOTHERAPEUTICS (HONG KONG) LIMITED
    Inventors: Hung-Kai Chen, Daw-Tsun Shih, Cheng-Lun Ku, Pei-Han Chung
  • Compound targeting IL-23A and TNF-alpha and uses thereof
    Patent number: 10793629
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: October 6, 2020
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, MACROGENICS, INC.
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • METHODS FOR TREATMENT OF HBV INFECTION
    Publication number: 20200289603
    Abstract: The present invention provides methods for treating hepatitis B virus (HBV) infection using antibodies which specifically bind to human IFN?.
    Type: Application
    Filed: June 1, 2020
    Publication date: September 17, 2020
    Applicant: ELIXIRON IMMUNOTHERAPEUTICS (HONG KONG) LIMITED
    Inventors: Hung-Kai CHEN, Daw-Tsun SHIH, Cheng-Lun KU, Pei-Han CHUNG
  • COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF
    Publication number: 20190016794
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Application
    Filed: August 1, 2018
    Publication date: January 17, 2019
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • Compound targeting IL-23A and TNF-alpha and uses thereof
    Patent number: 10059763
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: August 28, 2018
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, MACROGENICS, INC.
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF
    Publication number: 20160060338
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Application
    Filed: September 3, 2015
    Publication date: March 3, 2016
    Inventors: RACHEL REBECCA BARRETT, LESLIE S. JOHNSON, SANJAYA SINGH, KATHLEEN LAST-BARNEY, DAW-TSUN SHIH, PATRICIA GIBLIN, SCOTT BRODEUR, NELAMANGALA NAGARAJA